|
David S. Tierney MD served as the President and Chief Executive Officer (and as a member of the board of directors) of Valera Pharmaceuticals Inc. a specialty pharmaceutical company between August 2000 and April 2007 when Valera completed a merger with Indevus Pharmaceuticals Inc (IDEV:NASDAQ). From January 2000 to August 2000 Dr. Tierney served as President of Biovail Technologies a division of Biovail Corporation a Canadian drug delivery company where he was responsible for all of Biovail’s research and development regulatory and clinical activities. From March 1997 to January 2000 Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation where he was responsible for all research and development activities and for drug development medical affairs worldwide regulatory affairs and chemical process development as well as being part of the executive management team. From December 1989 to March 1997 Dr. Tierney was employed by Élan Corporation a pharmaceutical company in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin Ireland and was subsequently trained in internal medicine. Dr. Tierney is a director of NexMed Inc (NEXM: NASDAQ) and Catalyst Pharmaceutical Partners (CPRX: NASDAQ). | 